Verified ComparisonLast updated: 19 March 2026
Tirzepatide vs AOD-9604
Tirzepatide is an approved dual GLP-1/GIP agonist. AOD-9604 is an HGH-derived lipid-selective peptide.
Tirzepatide
Metabolic
4.6/ 5
A
AOD-9604
Metabolic
3.7/ 5
B
Editor's note
Tirzepatide is approved; AOD-9604 is investigational and lipid-selective.
| Criterion | Tirzepatide | AOD-9604 |
|---|---|---|
| Mechanism | GLP-1 + GIP agonism | HGH lipid fragment |
| Regulatory approval | Approved (AU and globally) | Investigational |
| Weight loss (trials) | Robust (18-22%) | Moderate |
| Lipid-selectivity | Moderate | High |
| Lean-mass preservation | Variable | Optimized |
Frequently asked questions
Tirzepatide; approved with clinical evidence exceeding AOD-9604.
Want to read the full reviews?